Literature DB >> 18499705

Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.

Deanna M Barch1, Cameron S Carter.   

Abstract

This overview describes the goals and objectives of the second conference conducted as part of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. This second conference was informed by a series of online surveys and brought together basic and clinical scientists from academia and industry to address the concerns central to each field of research. Our goal was to develop recommendations for future research addressing the psychometric and practical challenges involved in translating paradigms from cognitive neuroscience into tasks that are feasible for use in the treatment discovery and development process. In this overview article, we describe the series of talks that were presentations at the conference. This article serves as an introduction to the set of articles included in this special issue that provide overviews and discussions of the issues raised and the recommendations made in these talks and in the subsequent discussions at the meeting. In addition, we describe the online surveys conducted in the month before the conference that were used to obtain suggestions from the field as to important task selection criteria and to generate initial benchmark goals for psychometric development for cognitive neuroscience tasks.

Entities:  

Mesh:

Year:  2008        PMID: 18499705      PMCID: PMC2632448          DOI: 10.1093/schbul/sbn037

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  11 in total

1.  Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective.

Authors:  Wayne S Fenton; Ellen L Stover; Thomas R Insel
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.

Authors:  Keith H Nuechterlein; Trevor W Robbins; Haim Einat
Journal:  Schizophr Bull       Date:  2005-09-08       Impact factor: 9.306

3.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

4.  The measurement of differential deficit.

Authors:  L J Chapman; J P Chapman
Journal:  J Psychiatr Res       Date:  1978       Impact factor: 4.791

Review 5.  Demonstrating specific cognitive deficits: a psychometric perspective.

Authors:  M E Strauss
Journal:  J Abnorm Psychol       Date:  2001-02

Review 6.  A process-oriented approach for averting confounds resulting from general performance deficiencies in schizophrenia.

Authors:  R A Knight; S M Silverstein
Journal:  J Abnorm Psychol       Date:  2001-02

Review 7.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

8.  Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Authors:  Cameron S Carter; Deanna M Barch; Robert W Buchanan; Ed Bullmore; John H Krystal; Jonathan Cohen; Mark Geyer; Michael Green; Keith H Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Journal:  Biol Psychiatry       Date:  2008-05-07       Impact factor: 13.382

Review 9.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

10.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors:  Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal:  Arch Gen Psychiatry       Date:  2007-06
View more
  24 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

Review 2.  Genetic architecture of declarative memory: implications for complex illnesses.

Authors:  Carrie E Bearden; Katherine H Karlsgodt; Peter Bachman; Theo G M van Erp; Anderson M Winkler; David C Glahn
Journal:  Neuroscientist       Date:  2011-08-10       Impact factor: 7.519

Review 3.  CNTRICS final task selection: working memory.

Authors:  Deanna M Barch; Marc G Berman; Randy Engle; Jessica Hurdelbrink Jones; John Jonides; Angus Macdonald; Derek Evan Nee; Thomas S Redick; Scott R Sponheim
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

4.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 5.  Investigating the mechanism(s) underlying switching between states in bipolar disorder.

Authors:  Jared W Young; Davide Dulcis
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

6.  Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.

Authors:  Holly Moore; Mark A Geyer; Cameron S Carter; Deanna M Barch
Journal:  Neurosci Biobehav Rev       Date:  2013-09-30       Impact factor: 8.989

Review 7.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

8.  Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients.

Authors:  Jihae Noh; Ji-Hae Kim; Kyung Sue Hong; Nara Kim; Hee Jung Nam; Dongsoo Lee; Se Chang Yoon
Journal:  J Korean Med Sci       Date:  2010-01-25       Impact factor: 2.153

9.  Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.

Authors:  Hsun-Hua Chou; Jo A Talledo; Sarah N Lamb; Wesley K Thompson; Neal R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2013-01-12       Impact factor: 4.530

Review 10.  Recent advances in treating cognitive impairment in schizophrenia.

Authors:  Cherrie Galletly
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.